Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium

Documenti analoghi

• A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRD neg remission after intensive induction
  di: Konstanze Döhner, et al.
  Pubblicazione: (2025)
• Constructing MRD codes by switching
  di: Shi, Minjia, et al.
  Pubblicazione: (2022)
• Algebraic structures of MRD Codes
  di: de la Cruz, Javier, et al.
  Pubblicazione: (2015)
• Constructing MRD codes by switching
  di: Minjia Shi, et al.
  Pubblicazione: (2024)
• Analysis of Patients With Monocytic and Monocytic‐Like Acute Myeloid Leukemia, Including AML ‐ M4 and AML ‐ M5 , Treated With Venetoclax Plus Azacitidine
  di: Marina Konopleva, et al.
  Pubblicazione: (2026)